Last reviewed · How we verify
NCT06727773
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Phase 2 trial testing Memantine in Breast Cancer in 90 participants. Currently enrolling.
31 October 2028
Quick facts
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 90 |
| Start date | 7 May 2025 |
| Primary completion | 31 October 2028 |
| Estimated completion | 31 October 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Memantine (MEMANTINE) — full drug profile →
- Placebo medication
- Exercise Intervention
- Exercise Control
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Locally Advanced Breast Cancer — all drugs for Locally Advanced Breast Cancer →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Cognitive Decline — all drugs for Cognitive Decline →
Sponsor
UNC Lineberger Comprehensive Cancer Center — full company profile →
Who can join
18 and older, female only, with Breast Cancer or Locally Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real \& Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and underlying CRCI biomarkers. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, brain-derived neurotrophic factor (BDNF), inflammatory markers, and frailty at multiple time points.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06727773
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Memantine
Trials testing the same drug.
- NCT06914310 — Memantine as an Additive Therapy in Patients With Traumatic Brain Injury · Phase 2, PHASE3 · not yet recruiting
- NCT07417670 — Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease · Phase 4 · completed
- NCT05418049 — Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge · Phase 2 · active not recruiting
- NCT05013892 — NTS-WBRT in Brain Metastases · Phase 2 · recruiting
- NCT04588246 — Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patient · Phase 3 · terminated
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other UNC Lineberger Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06656936 — The PharmFIT Study · NA · not yet recruiting
- NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
- NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
- NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
- NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06727773 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06727773.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing